Dat	e : 3. marts 2025		
You	ı r name : Berit Andersen		
Mar	nuscript title: PRSONAL a ra	ndomized clinical trial about	risk-stratified breast cancer screening
	nuscript number (if known		
IVIA	nuscript number (ii known	1.	
are r third comi list a	elated to the content of yo parties whose interests m mitment to transparency a relationship/activity/inter	our manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. ps/activities/interests as they relate to the current
manı	uscript only.		
perta antih In ite	ains to the epidemiology of hypertensive medication, evaluation, e	hypertension, you should wen if that medication is n port for the work reporte	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plar	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
Tim 1	e frame: Since the initial plan	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
		whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk	(e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk	(e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk	(e.g., if payments were made to you or to your institution) Grant reference number NNF210C0070842
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk	(e.g., if payments were made to you or to your institution) Grant reference number NNF210C0070842
Tim	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk Foundation	(e.g., if payments were made to you or to your institution) Grant reference number NNF210C0070842
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk	(e.g., if payments were made to you or to your institution) Grant reference number NNF210C0070842
Tim	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. e frame: past 36 months	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk Foundation	(e.g., if payments were made to you or to your institution) Grant reference number NNF210C0070842
Tim	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk Foundation	(e.g., if payments were made to you or to your institution) Grant reference number NNF210C0070842

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending None	4	Consulting fees	⊠ None
lectures, presentations, speakers bureaus, manuscript writing or educational events Support for attending meetings and/or travel None None			
lectures, presentations, speakers bureaus, manuscript writing or educational events			
educational events 6 Payment for expert testimony None 7 Support for attending meetings and/or travel 8 Patents planned, issued or None	5	lectures, presentations, speakers bureaus,	⊠ None
7 Support for attending meetings and/or travel 8 Patents planned, issued or None			
7 Support for attending meetings and/or travel 8 Patents planned, issued or None	6	Payment for expert	⊠ None
8 Patents planned, issued or None			
8 Patents planned, issued or None			
8 Patents planned, issued or None	7	Support for attending	⊠ None
8 Patents planned, issued or None	, ,		△ None
	8	Patents planned issued or	⊠ None
		T	None
9 Participation on a Data 🛛 None	a	Participation on a Data	⊠ None
Safety Monitoring Board			None
or Advisory Board			
10 Leadership or fiduciary None	10	Loodorchin or fiducions	
10 Leadership or fiduciary role in other board,	10		⊠ None
society, committee or			
advocacy group, paid or			
unpaid		unpaid	
11 Stock or stock options	11	Stock or stock options	⊠ None
		·	
12 Receipt of equipment,	12	Receipt of equipment.	⊠ None
materials, drugs, medical	_ _	materials, drugs, medical	
writing, gifts or other			
services		services	
13 Other financial or non- None	13	Other financial or non-	⊠ None
financial interests		financial interests	

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Date	e : 3. marts 2025		
	r name: Line Hjøllund Pe	edersen	
			risk-stratified breast cancer screening
	nuscript number (if known		_
IVIAI	iuscript number (ii known	J·	
are ro third comr list a	elated to the content of yo parties whose interests m nitment to transparency a relationship/activity/inter	our manuscript. "Related" ay be affected by the cond nd does not necessarily in est, it is preferable that yo	
	ollowing questions apply t <u>uscript only</u> .	o the author's relationshi	os/activities/interests as they relate to the <u>current</u>
perta	ins to the epidemiology of	hypertension, you should	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.
	m #1 below, report all sup r items, the time frame for	·	d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plar		
1	All support for the present	☐ None	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Novo Nordisk Foundation	Grant reference number NNF21OC0070842
	No time limit for this		
	No time limit for this item.		
			Click TAD in last years and system warre
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		Click TAB in last row to add extra rows
	e frame: past 36 months		Click TAB in last row to add extra rows
Time	Grants or contracts from	⊠ None	Click TAB in last row to add extra rows
	Grants or contracts from any entity (if not indicated	⊠ None	Click TAB in last row to add extra rows
	Grants or contracts from	⊠ None ⊠ None	Click TAB in last row to add extra rows

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending None	4	Consulting fees	⊠ None
lectures, presentations, speakers bureaus, manuscript writing or educational events Support for attending meetings and/or travel None None			
lectures, presentations, speakers bureaus, manuscript writing or educational events			
educational events 6 Payment for expert testimony None 7 Support for attending meetings and/or travel 8 Patents planned, issued or None	5	lectures, presentations, speakers bureaus,	⊠ None
7 Support for attending meetings and/or travel 8 Patents planned, issued or None			
7 Support for attending meetings and/or travel 8 Patents planned, issued or None	6	Payment for expert	⊠ None
8 Patents planned, issued or None			
8 Patents planned, issued or None			
8 Patents planned, issued or None	7	Support for attending	⊠ None
8 Patents planned, issued or None	, ,		△ None
	8	Patents planned issued or	⊠ None
		T	None
9 Participation on a Data 🛛 None	a	Participation on a Data	⊠ None
Safety Monitoring Board			None
or Advisory Board			
10 Leadership or fiduciary None	10	Loodorchin or fiducions	
10 Leadership or fiduciary role in other board,	10		⊠ None
society, committee or			
advocacy group, paid or			
unpaid		unpaid	
11 Stock or stock options	11	Stock or stock options	⊠ None
		·	
12 Receipt of equipment,	12	Receipt of equipment.	⊠ None
materials, drugs, medical	_ _	materials, drugs, medical	
writing, gifts or other			
services		services	
13 Other financial or non- None	13	Other financial or non-	⊠ None
financial interests		financial interests	

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Dat	e: 3. marts 2025		
	ır name: Pia Rørbæk Kar	mstrun	
	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	risk-stratified breast cancer screening
	nuscript number (if knowr		
IVIA	iluscript number (ii knowi	1).	
are r third comi list a	elated to the content of your parties whose interests mail mitment to transparency a relationship/activity/inter	our manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	
	uscript only.	o the author's relationship	ps/activities/interests as they relate to the <u>current</u>
perta	ains to the epidemiology of	f hypertension, you should	defined broadly. For example, if your manuscript dideclare all relationships with manufacturers of ot mentioned in the manuscript.
	em #1 below, report all sup r items, the time frame for	·	d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plai	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
Tim	All support for the present	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
	1	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk	(e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk	(e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk	(e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk	(e.g., if payments were made to you or to your institution) Grant reference number NNF210C0070842
Tim	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk Foundation	(e.g., if payments were made to you or to your institution) Grant reference number NNF210C0070842
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. e frame: past 36 months	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk	(e.g., if payments were made to you or to your institution) Grant reference number NNF210C0070842
Tim	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk Foundation	(e.g., if payments were made to you or to your institution) Grant reference number NNF210C0070842
Tim	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk Foundation	(e.g., if payments were made to you or to your institution) Grant reference number NNF210C0070842

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending None	4	Consulting fees	⊠ None
lectures, presentations, speakers bureaus, manuscript writing or educational events Support for attending meetings and/or travel None None			
lectures, presentations, speakers bureaus, manuscript writing or educational events			
educational events 6 Payment for expert testimony None 7 Support for attending meetings and/or travel 8 Patents planned, issued or None	5	lectures, presentations, speakers bureaus,	⊠ None
7 Support for attending meetings and/or travel 8 Patents planned, issued or None			
7 Support for attending meetings and/or travel 8 Patents planned, issued or None	6	Payment for expert	⊠ None
8 Patents planned, issued or None			
8 Patents planned, issued or None			
8 Patents planned, issued or None	7	Support for attending	⊠ None
8 Patents planned, issued or None	, ,		△ None
	8	Patents planned issued or	⊠ None
		T	None
9 Participation on a Data 🛛 None	a	Participation on a Data	⊠ None
Safety Monitoring Board			None
or Advisory Board			
10 Leadership or fiduciary None	10	Loodorchin or fiducions	
10 Leadership or fiduciary role in other board,	10		⊠ None
society, committee or			
advocacy group, paid or			
unpaid		unpaid	
11 Stock or stock options	11	Stock or stock options	⊠ None
		·	
12 Receipt of equipment,	12	Receipt of equipment.	⊠ None
materials, drugs, medical	_ _	materials, drugs, medical	
writing, gifts or other			
services		services	
13 Other financial or non- None	13	Other financial or non-	⊠ None
financial interests		financial interests	

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Dat	e: 3. marts 2025		
	Ir name: Ilse Vejborg		
		ndomized clinical trial about	risk-stratified breast cancer screening
	nuscript number (if knowr		
IVIA	nuscript number (ii knowi	ı)·	
are r third comr list a	elated to the content of your parties whose interests maitment to transparency a relationship/activity/inter	our manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	
	rollowing questions apply t uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta	ains to the epidemiology of	f hypertension, you should	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.
	em #1 below, report all sup r items, the time frame for		d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial pla	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
Tim 1	All support for the present	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
		whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk	(e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk	(e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk	(e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk	(e.g., if payments were made to you or to your institution) Grant reference number NNF210C0070842
Tim	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk Foundation	(e.g., if payments were made to you or to your institution) Grant reference number NNF210C0070842
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. e frame: past 36 months	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk	(e.g., if payments were made to you or to your institution) Grant reference number NNF210C0070842
Tim	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk Foundation	(e.g., if payments were made to you or to your institution) Grant reference number NNF210C0070842
Tim	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. e frame: past 36 months Grants or contracts from any entity (if not indicated	whom you have this relationship or indicate none (add rows as needed) nning of the work None Novo Nordisk Foundation	(e.g., if payments were made to you or to your institution) Grant reference number NNF210C0070842

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending None	4	Consulting fees	⊠ None
lectures, presentations, speakers bureaus, manuscript writing or educational events Support for attending meetings and/or travel None None			
lectures, presentations, speakers bureaus, manuscript writing or educational events			
educational events 6 Payment for expert testimony None 7 Support for attending meetings and/or travel 8 Patents planned, issued or None	5	lectures, presentations, speakers bureaus,	⊠ None
7 Support for attending meetings and/or travel 8 Patents planned, issued or None			
7 Support for attending meetings and/or travel 8 Patents planned, issued or None	6	Payment for expert	⊠ None
8 Patents planned, issued or None			
8 Patents planned, issued or None			
8 Patents planned, issued or None	7	Support for attending	⊠ None
8 Patents planned, issued or None	, ,		△ None
	8	Patents planned issued or	⊠ None
		T	None
9 Participation on a Data 🛛 None	a	Participation on a Data	⊠ None
Safety Monitoring Board			None
or Advisory Board			
10 Leadership or fiduciary None	10	Loodorchin or fiducions	
10 Leadership or fiduciary role in other board,	10		⊠ None
society, committee or			
advocacy group, paid or			
unpaid		unpaid	
11 Stock or stock options	11	Stock or stock options	⊠ None
		·	
12 Receipt of equipment,	12	Receipt of equipment.	⊠ None
materials, drugs, medical	_ _	materials, drugs, medical	
writing, gifts or other			
services		services	
13 Other financial or non- None	13	Other financial or non-	⊠ None
financial interests		financial interests	

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Dat	e : 3. marts 2025		
You	r name: Antonis Antonio	u	
Man	nuscript title: PRSONAL a rai	ndomized clinical trial about	risk-stratified breast cancer screening
Mai	nuscript number (if known):	
are rethird comress and the second commercial commercia	elated to the content of yo parties whose interests ma nitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. Dos/activities/interests as they relate to the current
perta antih In ite	nins to the epidemiology of hypertensive medication, ex	hypertension, you should yen if that medication is n port for the work reporte	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months.
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan	•	
1	All support for the present	□ None	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Novo Nordisk Foundation	Grant reference number NNF21OC0070842
	No time limit for this		
	item.		
			Click TAB in last row to add extra rows
			Click TAB III last Tow to add extra Tows
Time	e frame: past 36 months		
2	Grants or contracts from	☐ None	
2	any entity (if not indicated	Cancer Research UK	PPRPGM-Nov20\100002
	in item #1 above).	Cancer Research UK	SEBCD3-2024/100001
2	D		
3	Royalties or licenses	None	
		Creator of the BOADICEA model.	Licensed from Cambridge Enterprise (University of Cambridge) for commercial purposes.

4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None	
6	Payment for expert	⊠ None	
	testimony	⊠ None	
	,		
_		—	
7	Support for attending meetings and/or travel	⊠ None	
	meetings and/or traver		
8	Patents planned, issued or	⊠ None	
	pending		
9	Participation on a Data	⊠ None	
	Safety Monitoring Board		
	or Advisory Board		
10	Leadership or fiduciary	⊠ None	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock options	⊠ None	
12	Receipt of equipment,	⊠ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	⊠ None	
	financial interests		

 $oxed{\boxtimes}$ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date	e : 3. marts 2025		
You	r name: Janne Bigaard		
Man	uscript title: PRSONAL a rai	ndomized clinical trial about	risk-stratified breast cancer screening
Mar	nuscript number (if known):	
are re third comr list a The f	elated to the content of yo parties whose interests ma nitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the control does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. ps/activities/interests as they relate to the current
perta antih In ite	ins to the epidemiology of ypertensive medication, ev	hypertension, you should yen if that medication is n port for the work reporte	defined broadly. For example, if your manuscript declare all relationships with manufacturers of not mentioned in the manuscript. d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan	ning of the work	
1	All support for the present manuscript (e.g., funding, provision of study	☐ None Novo Nordisk	
	•	Foundation	Grant reference number NNF21OC0070842
	materials, medical writing, article processing charges, etc.)	Foundation	Grant reference number NNF21OC0070842
	materials, medical writing, article processing charges,	Foundation	Grant reference number NNF21OC0070842
	materials, medical writing, article processing charges, etc.) No time limit for this	Foundation	Click TAB in last row to add extra rows
Time	materials, medical writing, article processing charges, etc.) No time limit for this item.	Foundation	
Time	materials, medical writing, article processing charges, etc.) No time limit for this	Foundation	
Time 2	materials, medical writing, article processing charges, etc.) No time limit for this item. e frame: past 36 months Grants or contracts from any entity (if not indicated	Foundation None	
1	materials, medical writing, article processing charges, etc.) No time limit for this item. e frame: past 36 months Grants or contracts from		

4	Consulting fees	⊠ None		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None		
6	Payment for expert testimony	⊠ None		
7	Support for attending meetings and/or travel	⊠ None		
,		None		
8	⊠ None			
	Patents planned, issued or pending	None		
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None		
		None		
40				
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None		
11	Stock or stock options	⊠ None		
		Zi None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None		
14		Notice		
13	Other financial or non- financial interests	⊠ None		
		ES NOTE		
		<u> </u>		

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Date	e : 3. marts 2025		
	r name: Stig Egil Bojese	n	
	3 3 3		risk-stratified breast cancer screening
Mar	nuscript number (if known).	
IVIGI	Tuscript number (ii known	<i>J</i> ·	
are re third comr	elated to the content of yo parties whose interests m	ur manuscript. "Related" ay be affected by the control of does not necessarily in	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit ent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
	ollowing questions apply to uscript only.	o the author's relationshi	os/activities/interests as they relate to the <u>current</u>
perta	ins to the epidemiology of	hypertension, you should	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.
	m #1 below, report all sup r items, the time frame for		d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plar		
1	All support for the present	☐ None	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Novo Nordisk Foundation	Grant reference number NNF21OC0070842
	No time limit for this item.		
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		
	·		
2	Grants or contracts from any entity (if not indicated in item #1 above).	⋈ None	
3	Royalties or licenses		

4	Consulting fees	⊠ None		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None		
6	Payment for expert testimony	⊠ None		
7	Support for attending meetings and/or travel	⊠ None		
,		None		
8	⊠ None			
	Patents planned, issued or pending	None		
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None		
		None		
40				
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None		
11	Stock or stock options	⊠ None		
		Zi None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None		
14		Notice		
13	Other financial or non- financial interests	⊠ None		
		ES NOTE		
		<u> </u>		

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal